Regulatory T-cells in Psoriasis Patients as Targets for Therapy

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to understand which therapies will suppress effector cells and promote regulatory T cells and To test whether patients with a better response to therapy and longer psoriasis-free periods develop a higher numerical ratio of regulatory to effectors T-cells and/or regulatory cells more able to suppress the effectors.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Aberdeen
• Collaborator: NHS Grampian
• Treatments: Acitretin; Adalimumab; Betamethasone; Calcipotriene; Etanercept; Infliximab

Criteria

Inclusion Criteria:

• • Male and female patients in the age range from 18 to 70 who are diagnosed with moderate to severe psoriasis.

• Patients must be treatment free for at least 2 weeks for topical application and 4 weeks for systemic treatment of psoriasis.

• Women of child bearing potential must be on reliable contraception.

• Patients in whom a decision to treat with one of the following therapies has already been made based on normal clinical care:

• Dovobet

• Neotigason

• Narrow-band UVB

• Etanercept

• Adalimumab

• Infliximab

• 10 normal controls

Exclusion Criteria:

• • Children below 18 years and patients over 70 years.

• Pregnant and lactating patients.

• Patients who are known to have immunosuppressive disease (e.g. HIV) or on any immunosuppressive therapy.